Work

Randomized phase 2 study of PEGPH20 Plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA)

Year: 2017

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx369.145

Authors: S.R. Hingorani, A. Bullock, T. Seery, L. Zheng, D. Sigal, P.S. Ritch, F.S. Braiteh, M. Zalupski, N. Bahary, W. Harris, J. Pu, C. Aldrich, S. Khelifa, W. Wu, D. Chondros, P. Jiang, A. Hendifar

Institutions: Fred Hutch Cancer Center, Beth Israel Deaconess Medical Center, University of California, Irvine, Johns Hopkins University, Johns Hopkins Hospital, Froedtert Hospital, Medical College of Wisconsin, Comprehensive Cancer Centers of Nevada, University of Michigan, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, University of Washington, Halozyme Therapeutics (United States), Cedars-Sinai Medical Center

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2761525187

FWCI: 0.323

Cites:

Cited by: 4

Related to: 10